American Association for Cancer Research
Browse

Supplementary Figures and Legends from Secretory IgM Exacerbates Tumor Progression by Inducing Accumulations of MDSCs in Mice

Download (3.62 MB)
journal contribution
posted on 2023-04-03, 23:20 authored by Chih-Hang Anthony Tang, Shiun Chang, Ayumi Hashimoto, Yi-Ju Chen, Chang Won Kang, Anthony R. Mato, Juan R. Del Valle, Dmitry I. Gabrilovich, Chih-Chi Andrew Hu

S1. Crosslinking and preparation of oligomeric HEL. S2. Oligomeric HEL crosslinks the BCR, and induces robust BCR signal transduction in MD4+/-/Eμ-TCL1+/+ B cells. S3. Oligomeric HEL activates a more rapid BCR signaling than F(ab')2 in MD4+/- and MD4+/-/Eμ-TCL1+/+ B cells. S4. CD11b+/Ly6G+ granulocytic cells or CD11b+/Ly6C+ monocytic cells do not accumulate in the blood and spleens of 6-month-old WT, MD4+/- and μS-/- mice. S5. B cells and CLL cells from MD4+/-/Eμ-TCL1+/+ and Eμ-TCL1+/+ but not μS-/-/E�-TCL1+/+ mice produce sIgM; human CLL cells also produce and secrete IgM. S6. Decreased percentages of CD11b+/Ly6G+ granulocytic cells in spleens of 6-week-old μS-/-/E�-TCL1+/+ mice; decreased percentages of CD11b+/Ly6G+ granulocytic cells and CD11b+/Ly6C+ monocytic cells in the bone marrow of 6-month-old μS-/-/Eμ-TCL1+/+ mice; increased percentages of CD11b+/Ly6G+ granulocytic cells and CD11b+/Ly6C+ monocytic cells in the bone marrow of 6-week-old MD4+/-/Eμ-TCL1+/+ mice; and increased percentages of CD11b+/Ly6G+ granulocytic cells in the bone marrow of 6-month-old MD4+/-/Eμ-TCL1+/+ mice. S7. CD11b+/Ly6G+ granulocytic cells can be purified from the spleens and peripheral blood of MD4+/-/Eμ�-TCL1+/+ mice. S8. CD11b+/Ly6G+ granulocytic cells purified from the spleens or bone marrow of LLC-grafted WT and μS-/- mice have small or little effect in suppressing T cell proliferation.

Funding

NIH

NCI

History

ARTICLE ABSTRACT

Chronic lymphocytic leukemia (CLL) cells can secrete immunoglobulin M. However, it is not clear whether secretory IgM (sIgM) plays a role in disease progression. We crossed the Eμ-TCL1 mouse model of CLL, in which the expression of human TCL1 oncogene was driven by the V(H) promoter-Ig(H)-Eμ enhancer, with MD4 mice whose B cells produced B-cell receptor (membrane-bound IgM) and sIgM with specificity for hen egg lysozyme (HEL). CLL cells that developed in these MD4/Eμ-TCL1 mice reactivated a parental Ig gene allele and secreted IgM, and did not recognize HEL. The MD4/Eμ-TCL1 mice had reduced survival, increased myeloid-derived suppressor cells (MDSC), and decreased numbers of T cells. We tested whether sIgM could contribute to the accumulation of MDSCs by crossing μS–/– mice, which could not produce sIgM, with Eμ-TCL1 mice. The μS–/–/Eμ-TCL1 mice survived longer than Eμ-TCL1 mice and developed decreased numbers of MDSCs which were less able to suppress proliferation of T cells. We targeted the synthesis of sIgM by deleting the function of XBP-1s and showed that targeting XBP-1s genetically or pharmacologically could lead to decreased sIgM, accompanied by decreased numbers and reduced functions of MDSCs in MD4/Eμ-TCL1 mice. Additionally, MDSCs from μS–/– mice grafted with Lewis lung carcinoma were inefficient suppressors of T cells, resulting in slower tumor growth. These results demonstrate that sIgM produced by B cells can upregulate the functions of MDSCs in tumor-bearing mice to aggravate cancer progression. In a mouse model of CLL, production of secretory IgM led to more MDSCs, fewer T cells, and shorter survival times for the mice. Thus, secretory IgM may aggravate the progression of this cancer. Cancer Immunol Res; 6(6); 696–710. ©2018 AACR.